GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spermosens AB (XSAT:SPERM) » Definitions » Net Current Asset Value

Spermosens AB (XSAT:SPERM) Net Current Asset Value : kr0.00 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Spermosens AB Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Spermosens AB's net current asset value per share for the quarter that ended in Mar. 2025 was kr0.00.

The historical rank and industry rank for Spermosens AB's Net Current Asset Value or its related term are showing as below:

During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Spermosens AB was 43.13. The lowest was 3.88. And the median was 13.61.

XSAT:SPERM's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.24
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Spermosens AB Net Current Asset Value Historical Data

The historical data trend for Spermosens AB's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spermosens AB Net Current Asset Value Chart

Spermosens AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial -0.02 0.06 -0.03 -0.04 -

Spermosens AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 - - - -

Competitive Comparison of Spermosens AB's Net Current Asset Value

For the Diagnostics & Research subindustry, Spermosens AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spermosens AB's Price-to-Net-Current-Asset-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Spermosens AB's Price-to-Net-Current-Asset-Value falls into.


;
;

Spermosens AB Net Current Asset Value Calculation

Spermosens AB's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.758-3.699-0-0)/757.795
=-0.00

Spermosens AB's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(3.814-1.837-0-0)/1356.181
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spermosens AB  (XSAT:SPERM) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Spermosens AB Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Spermosens AB's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Spermosens AB Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.

Spermosens AB Headlines

No Headlines